Clearmind Advances Alcohol Use Disorder Trial with First Patient Doses — Clearmind Medicine Inc.

Event summary

Clearmind enrolled the first two patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial on September 11, 2026.
The trial is being conducted at Hadassah Medical Center in Jerusalem, Israel.
CMND-100 has previously been evaluated in healthy participants but this marks its first use in AUD patients.
The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100.

The big picture

Clearmind's progress in its CMND-100 trial reflects the broader push to develop non-hallucinogenic psychedelic-derived treatments for addiction disorders. The company's focus on scalable solutions for underserved conditions like AUD positions it within an emerging sector that combines biopharmaceutical innovation with mental health treatment. Success in this trial could validate its proprietary neuroplastogen approach and attract further investment in psychedelic therapeutics.

What we're watching

Trial Momentum: How quickly Clearmind can enroll additional patients and meet key clinical milestones.
Regulatory Pathway: Whether CMND-100 can demonstrate sufficient efficacy and safety to advance through later-stage trials.
Competitive Positioning: The pace at which Clearmind can differentiate itself in the growing psychedelic therapeutics space.